Personalized Medicine Biomarkers Market Projected To Reach USD 43.07 Billion By 2030


 San Francisco, 13 Feb 2023: The Report Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Diagnostics), By Indication (Oncology, Neurology), By Test Location, By Region, And Segment Forecasts, 2022 - 2030

The global personalized medicine biomarkers market size is expected to reach USD 43.07 billion by 2030, expanding at a CAGR of 15.51% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.

Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.

Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.

Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.

Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.

Access Research Report of Personalized Medicine Biomarkers Market @ https://www.grandviewresearch.com/industry-analysis/personalized-medicine-biomarkers-market-report

Personalized Medicine Biomarkers Market Report Highlights

  • Early detection/screening segment is expected to grow at the fastest CAGR owing to the need to provide early treatment to patients
  • Oncology segment held the largest market share in 2021 owing to the rising prevalence of cancer and the wide availability of FDA-approved personalized biomarkers tests for cancer
  • North America held the largest market share attributable to the presence of improved healthcare infrastructure, rising prevalence of target diseases, and increasing government funding for innovation in biomarkers

List of Key Players in the Personalized Medicine Biomarkers Market

  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc.
  • Genome Medical, Inc.
  • Coriell Life Sciences.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories
  • FOUNDATION MEDICINE, INC.
  • Illumina, Inc.
  • Guardant Health

Access Press Release of Personalized Medicine Biomarkers Market @ https://www.grandviewresearch.com/press-release/global-personalized-medicine-biomarkers-market

 

Comments

Post a Comment

Popular posts from this blog

Asia Pacific PoC Diagnostics Market Growth Opportunities, Industry Analysis And Forecast: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Asia Pacific PoC Diagnostics Market  Analysis And Segment Forecasts To 2020 The Asia Pacific point of care (PoC) diagnostics market is expected to reach USD 5,427.1 million by 2020, according to a new study by Grand View Research, Inc. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of PoC products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expect
Read more

Food Additives Market Size & Share Hit USD 55.53 Billion By 2022 : Grand View Research Inc.

Image
San Francisco, 17 October 2019:   The Report   Global Food Additives Market   Analysis By Product Flavors & Enhancers (Natural, Artificial), Sweeteners (High Intensity, HFCS), Enzymes, Emulsifiers (Mono, Di-Glycerides, Lecithin, Stearoyl Lactylates, Sorbitan Esters), Shelf-life Stabilizers, Fat Replacers (Protein, Starch)] And Segment Forecast To 2022 Global food additives market is expected to reach USD 55.53 billion by 2022, according to a new study by Grand View Research, Inc. Food & beverage industry growth in BRICS and Middle East on account of rising domestic consumption and increasing foreign direct investments is expected to augment market growth. Asia Pacific is expected to be one of the most promising markets on account of growing domestic consumption in China and India owing to population growth and new product launches by food & beverage manufacturers. Availability of raw materials such as sorbitol and lactic acid in China, Indonesia, and Malaysia in light o
Read more

Integration Platform as a Service Market Valuation Is Expected To Exceed USD 2.70 Billion By 2025: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Integration Platform as a Service (IPaaS) Market  Analysis By Integration Type (API, Process, Application, Data), By Services, By Deployment (Cloud, On-Premise, Hybrid) By Region, And Segment Forecasts, 2018 – 2025 The global integration platform as a service (IPaaS) market is expected to reach USD 2.705.8 million by 2025, according to a new report by Grand View Research, Inc. Rising need of advanced systems to improve the process of deploying, developing, and managing enterprise applications globally has been a major factor driving market growth. In addition, recent developments in big data, cloud computing, and Internet of Things (IoT) within organizations’ processes also paved the way for greater development of IPaaS solutions. Integration Platform as a Service is an emerging technology where in the applications, process, data, and application programs are integrated. The integration enables enterprises to reduce the complexity
Read more